Reference

Compound medical formulation for treating diabetes mellitus with kidney-spleen deficiency and blood stasis syndromes

All Rights Reserved. Compound medical formulation for treating diabetes mellitus with kidney-spleen deficiency and blood stasis syndromes. Liu, Haitao; Feng, Guangbin; Ye, Chengyu (Peop. Rep. China ). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1879753 A 20 Dec 2006,8pp. (Chinese). (People's Republic of China). CODEN: CNXXEV. APPLICATION: CN 2010-17783 16 May 2006. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) The title medical formulation is prepd. from cooked Rehmannia glutinosa 15-20, Schisandra chinensis fruit 3-6, Cinnamomum cassia 1-3, Cornus officinalis 8-13, Polygonum multiflorum 12-17, Scrophularia 3-8, Panax ginseng 2-6, Astragalus membranaceus 10-15, Atractylodes chinensis 3-6, endothelium corneum of Gallus gallus 10-15, Salvia miltiorrhiza 10-16, glibenclamide 0.01-0.04, metformin 1.0-2.0, chromium picolinate 0.0001-0.0005, sodium selenite 0.00008-0.00013, zinc glycinate 0.02-0.07 and vanadic sulfate 0.000005-0.000010%. 14639-25-9 and 657-24-9 which are cas registry numbers of substances are two of reagents here. It is prepd. by pulverizing 1/5 Panax ginseng, glibenclamide and metformin to fine powder, mixing with chromium picolinate, sodium selenite, zinc glycinate and vanadic sulfate, grinding, decocting the residual Panax ginseng and the other Chinese medicine materials in water twice each for 2 h, filtrating, vacuum concg., adding the above fine powder, mixing, drying, pulverizing, sieving with 100 mesh screen and encapsulating. The product contg. Chinese medicine and western medicine has synergistic effect for lowering blood sugar with advantages of proper formulation, convenience to apply, good therapeutic effect and no adverse effect. .

Composition for preventing and treating cardiovascular disorders

All Rights Reserved. Composition for preventing and treating cardiovascular disorders. Mao, Frank Chiahung; Chen, Wen-Ying; Chiang, Yi-Chung; Cheng Chiang, Ling-Hui (Maxluck Biotechnology Corp., Taiwan). U.S. Pat. Appl. Publ. US 2007010426 A1 11 Jan 2007, 5pp. (English). (United States of America). CODEN: USXXCO. INCL: 514006000. APPLICATION: US 2005-218642 6 Sep 2005. PRIORITY: TW 2005-94122677 5 Jul 2005. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 17, 18 A compn. for preventing and treating cardiovascular disorders is disclosed. The compn. includes the lactoferrin and a trivalent chromium compd. The trivalent chromium (III) of the present invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium nicotinate, inorg. salts of trivalent chromium, org.In this experiment, several chemicals are used like 14639-25-9 and 16065-83-1 salts of trivalent chromium, and combinations thereof. The present invention also discloses a method for preventing and treating cardiovascular disease of an acceptor. .